| Name | Title | Contact Details |
|---|
Centinel Spine is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthEd is a specialized agency that uses education to help people develop the knowledge, skills, motivation, and confidence to manage important health decisions and activities and ultimately achieve better health outcomes.
CreoDent Prosthetics is a nationally recognized premier full service dental laboratory and a milling center located in New York. With 2 facilities in NYC and Newburgh, NY, CreoDent specialize in both implant and esthetic dentistry. CreoDent continues to grow and develop new products and services to our clients nationwide. Our products and services have given CreoDent its reputation as the finest dental laboratory to work with.
Essentia Health is an integrated health system serving patients in Minnesota, North Dakota, Wisconsin and Idaho. In the summer of 2010, Essentia Health brought together the operations of SMDC Health System, Brainerd Lakes Health, Innovis Health, Essentia Community Hospitals and Clinics, and the Essentia Institute of Rural Health. Essentia Health was originally formed in January 2004 through a partnership of the Benedictine Health System and SMDC Health System. In January 2008, Innovis Health joined Essentia Health and all of the hospitals and clinics owned by the Benedictine Health System were transferred to Essentia Community Hospitals and Clinics.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.